Allena Pharmaceuticals, which is developing enzymes for rare and severe metabolic and kidney disorders, filed on Friday with the SEC to raise up to $92 million in an initial public offering.
The Newton, MA-based company was founded in 2011 and it plans to list on the Nasdaq under the symbol ALNA. Credit Suisse, Jefferies and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
